Publication

Optimizing levofloxacin dose in the treatment of multidrug-resistant tuberculosis: An integrated PK/PD approach

Ghimire, S., 2019, [Groningen]: University of Groningen. 180 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 887 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3

    Final publisher's version, 1 MB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 10/04/2020

    Request copy

  • Chapter 5A

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 01/01/9999

    Request copy

  • Publishers version chapter 5A

    Final publisher's version, 667 KB, PDF document

  • Chapter 5B

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 10/04/2020

    Request copy

  • Chapter 6A

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 17/07/2020

    Request copy

  • Chapter 6B

    Final publisher's version, 1 MB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Chapter 8 Summary

    Final publisher's version, 953 KB, PDF document

  • Samenvatting

    Final publisher's version, 817 KB, PDF document

  • Acknowledgements

    Final publisher's version, 772 KB, PDF document

  • About the author

    Final publisher's version, 565 KB, PDF document

  • List of publications

    Final publisher's version, 607 KB, PDF document

  • Complete thesis

    Final publisher's version, 3 MB, PDF document

    Embargo ends: 01/01/9999

    Request copy

  • Propositions

    Final publisher's version, 254 KB, PDF document

Tuberculosis (TB) is an infectious disease that is transmitted through air from infected person through coughing, sneezing or talking. The tubercle bacillus or Mycobacterium tuberculosis is the causative organism of tuberculosis. When tubercle bacillus is resistant to two most important first line drugs: isoniazid and rifampicin, patients develop multi-drug resistant tuberculosis (MDR-TB). The treatment duration for MDR-TB lasts long, for at least 9-12 months and up to two years. Moreover, second-line medicines must be used that have far more side effects and are less effective. The treatment success results are unfavorable worldwide, which fails in nearly half of the treated MDR-TB patients. How can we improve the treatment results? This dissertation tries to contribute to the knowledge on one of the most important medicines for MDR-TB in order to ultimately improve the treatment results. Based on the results from levofloxacin levels in blood, we have shown that currently used levofloxacin dose in MDR-TB patients is insufficient. The medicine levels that are too low in combination with reduced bacterial sensitivity lead to an increased chance of therapy failure. Therapeutic drug monitoring enables clinicians to adjust dosage of medicines based on levels achieved in blood. Different patients on same dosages achieve a range of concentrations due to inter-individual variability. Therefore, knowledge about individual medicine levels, bacterial susceptibility and disease severity in the patient can help in adjusting drug dosages in individual patients. It’s time for precision medicine in the treatment of tuberculosis.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date10-Apr-2019
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-1531-4
Electronic ISBNs978-94-034-1530-7
Publication statusPublished - 2019

View graph of relations

Download statistics

No data available

ID: 78710118